Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION
6.1.2 INCREASING GERIATRIC POPULATION
6.1.3 INCREASE IN PIPELINE PRODUCTS
6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 INCREASING RESEARCH AND DEVELOPMENT
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD)
6.4 CHALLENGES
6.4.1 LIMITED ACCESS TO TREATMENT
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS
7 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE
7.1 OVERVIEW
7.2 DRY AMD
7.3 WET AMD
7.3.1 MEDICATIONS
7.3.2 ANTI-VEGF THERAPY
7.3.3 GENE THERAPY
7.3.4 SURGERY
8 EUROPE AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 SPECIALTY CLINICS
8.4 AMBULATORY SURGICAL CENTERS
8.5 HOME HEALTHCARE
8.6 OTHERS
9 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 RETAIL SALES
9.2.1 HOSPITAL PHARMACIES
9.2.2 RETAIL PHARMACIES
9.2.3 OTHERS
9.3 DIRECT TENDER
10 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION
10.1 EUROPE
10.1.1 GERMANY
10.1.2 FRANCE
10.1.3 U.K.
10.1.4 RUSSIA
10.1.5 ITALY
10.1.6 SPAIN
10.1.7 NETHERLANDS
10.1.8 SWITZERLAND
10.1.9 POLAND
10.1.10 TURKEY
10.1.11 AUSTRIA
10.1.12 HUNGARY
10.1.13 NORWAY
10.1.14 IRELAND
10.1.15 LITHUANIA
10.1.16 REST OF EUROPE
11 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: EUROPE
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 NOVARTIS AG
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENT
13.1.5.1 AGREEMENT
13.2 GENENTECH, INC.
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENT
13.3 BAYER AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 ADVERUM BIOTECHNOLOGIES, INC.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENT
13.5 ASTELLAS PHARMA INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENT
13.6 GRAYBUG VISION INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENT
13.7 GENSIGHT BIOLOGICS
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.7.4.1 EVENT
13.7.4.2 AWARD
13.8 IONIS PHARMACEUTICALS
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENT
13.8.4.1 EVENT
13.9 IVERIC BIO
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 JOHNSON &JOHNSON SERVICES, INC.
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.10.4.1 COLLABORATION
13.11 KODIAK SCIENCES INC.
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 MEIRAGTX LIMITED
13.12.1 COMPANY SNAPSHOT
13.12.2 PRODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENTS
13.12.3.1 EVENTS
13.12.3.2 AWARD
13.12.3.3 COLLABORATION
13.13 OCUGEN INC.
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENTS
13.13.3.1 INVESTMENT
13.13.3.2 CLINICAL TRIAL
13.14 PIXIUM VISION
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 PRODUCT PORTFOLIO
13.14.4 RECENT DEVELOPMENT
13.14.4.1 AWARD
13.15 REGENXBIO INC.
13.15.1 COMPANY SNAPSHOT
13.15.2 PRODUCT PORTFOLIO
13.15.3 RECENT DEVELOPMENTS
13.15.3.1 EVENT
13.15.3.2 COLLABORATION
13.15.3.3 CERTIFICATION
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 VARIOUS EXAMPLES OF OPHTHALMIC DEVICES ARE SUMMARIZED IN THE BELOW-GIVEN TABLE ACCORDING TO THEIR CLASSIFICATION
TABLE 2 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 EUROPE DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 8 EUROPE HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 14 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 16 EUROPE DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 18 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 20 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 21 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 22 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 23 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 GERMANY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 26 GERMANY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 27 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 28 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 29 GERMANY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 30 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 FRANCE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 32 FRANCE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 33 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 34 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 35 FRANCE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 36 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 U.K. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 38 U.K. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 39 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 40 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 41 U.K. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 RUSSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 44 RUSSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 45 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 46 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 47 RUSSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 48 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 ITALY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 50 ITALY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 51 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 52 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 53 ITALY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 54 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SPAIN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 56 SPAIN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 57 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 58 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 59 SPAIN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 60 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 NETHERLANDS WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 62 NETHERLANDS MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 63 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 64 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 65 NETHERLANDS RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 SWITZERLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 68 SWITZERLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 69 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 70 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 71 SWITZERLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 POLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 74 POLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 75 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 76 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 77 POLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 TURKEY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 80 TURKEY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 81 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 82 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 83 TURKEY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 AUSTRIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 86 AUSTRIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 87 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 88 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 89 AUSTRIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 90 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 HUNGARY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 92 HUNGARY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 93 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 94 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 95 HUNGARY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 96 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 NORWAY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 98 NORWAY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 99 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 100 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 101 NORWAY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 102 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 IRELAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 104 IRELAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 105 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 106 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 107 IRELAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 108 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 LITHUANIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 110 LITHUANIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)
TABLE 111 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)
TABLE 112 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)
TABLE 113 LITHUANIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 114 REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION
FIGURE 2 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DROC ANALYSIS
FIGURE 4 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRY AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET
FIGURE 16 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2021
FIGURE 17 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2021
FIGURE 21 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 22 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 23 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 24 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 25 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 26 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 27 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 28 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SNAPSHOT (2021)
FIGURE 29 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2021)
FIGURE 30 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 31 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 32 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE (2022-2029)
FIGURE 33 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY SHARE 2021 (%)
